Suppliers / Kenvue Brands

Kenvue Brands

United States Updated 9 July 2026

Kenvue Brands is an API and finished-dose manufacturer based in United States. It holds 2 active US drug master files. Its GMP standing is certified by US FDA. Its most recent recorded inspection, by US FDA, closed on 2 April 2026 as NAI.

2
active US DMFs
0
valid CEPs
2
registered plants 2 with an FDA FEI number
32
filings across 1 regulators
These figures were checked against the regulators' own files on 25 July 2026
Plants
2 of 2 confirmed
Inspections
8 of 8 confirmed
Sources: FDA Establishment Registration, read 4 May 2026. FDA drug inspection classifications, read 4 May 2026.

Inspection history

  • 2 April 2026 NAI US FDA
  • 10 February 2026 VAI US FDA
  • 27 January 2023 NAI US FDA
  • 7 October 2022 NAI US FDA
  • 3 May 2021 NAI US FDA
  • 7 July 2017 VAI US FDA
  • 9 December 2016 NAI US FDA
  • 21 September 2015 VAI US FDA

NAI means no action indicated, VAI means voluntary action indicated, and OAI means official action indicated.

Registered plants

Site FDA FEI
Fort Washington, United States 2510184
Lititz, United States 2510770

What they file, and where

Molecule Regulators Docs
Nicotine US FDA 2

Also appears on these molecule pages

Cetirizine finished dose Famotidine finished dose Ibuprofen finished dose Loperamide finished dose Minoxidil finished dose Nicotine API Pseudoephedrine finished dose

Filings and GMP by regulator

Regulator Filings GMP certificates
US FDA 32 2

Comparing suppliers?

Choose your molecules and target markets. Kenvue Brands comes back tiered against every other supplier able to file there.

Start for free
No sales call.

Open risk flags

  • 95 active litigation matters are on record.
  • The most recent inspection outcome was NAI, on 2 April 2026.

Sources on this page

FDA
Drug master files, establishment registration, inspection classifications
EDQM
Certificates of suitability
EudraGMDP and national regulators
GMP certificates